Potential roles for statins in critically ill patients

Pharmacotherapy

Volumn 27, Issue 9 I, 2007, Pages 1279-1296

  Weant, Kyle A ^a   Cook, Aaron M ^b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

3 hydroxy 3 methylglutaryl reductase inhibitors; Bacteremia; Critical care; HMG CoA reductase inhibitors; Pleiotropy; Sepsis; Statins; Stroke; Subarachnoid hemorrhage

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CITICOLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROTRECOGIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; NIMODIPINE; NITRIC OXIDE; PLACEBO; PRAVASTATIN; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR 1; SIMVASTATIN; THROMBIN; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1; WARFARIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BACTEREMIA; BRAIN VASOSPASM; CARDIOVASCULAR RISK; CELL CYCLE ARREST; CELL PROLIFERATION; CEREBRAL ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG MEGADOSE; DRUG RESEARCH; DRUG WITHDRAWAL; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LENGTH OF STAY; LONG TERM CARE; LUNG INFECTION; MEDICAL RECORD REVIEW; MORTALITY; NONHUMAN; PLEIOTROPY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SEPSIS; SEPTIC SHOCK; SKIN INFECTION; SMOOTH MUSCLE FIBER; SOFT TISSUE INFECTION; STROKE; SUBARACHNOID HEMORRHAGE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; VASOSPASM;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; BACTEREMIA; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; CRITICAL ILLNESS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; STROKE; VASOSPASM, INTRACRANIAL;

EID: 34548356919     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.9.1279     Document Type: Review

References (81)

1. Nash DT. Meeting national cholesterol education goals in clinical practice: a comparison of lovastatin and fluvastatin in primary prevention. Am J Cardiol 1996;78:26-31.
2. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 2006;145:520-30.
3. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230-5.
4. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191-3.
5. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
6. Albert MA, Danielson E, Rifai N, Ridker PM, for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE) - a randomized trial and cohort study. JAMA 2001;286:64-70.
7. Jialal I, Devaraj S. Antioxidants and atherosclerosis: don't throw out the baby with the bath water. Circulation 2003;107:926-8.
8. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial Circulation 2003;107:2409-15.
9. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-19.
10. Jarvisalo MJ, Toikka JO, Vasankari T, et al. HMG-CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999;147:237-42.
11. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl-(HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-5.
12. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999;30:1969-73.
13. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9.
14. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;2:1057-8.
15. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kindase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-10.
16. O'Driscoll G, Green D, Taylor RR. Simvastatin an HMG-coenzyme A reductase inhibitor improves endothelial function within 1 month. Circulation 1997;95:1126-31.
17. Pruefer D, Makowski J, Schnell M, et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation 2002;106:2104-10.
18. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001;103:926-33.
19. Yang Z, Kozai T, van der Loo B, et al. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol 2000;36:1691-7.
20. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3- methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83:490-500.
21. Bellosta S, Berhini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998;137(suppl):s101-9.
22. Borghaei RC, Sullivan C, Mochan E. Identification of a cytokine-induced repressor of interleukin-1 stimulated expression of stromelysin1 (MMP-3). J Biol Chem 1999;274: 2126-31.
23. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-63.
24. Ito T, Ikeda U, Yamamoto K, Shimada K. Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells. Atherosclerosis 2002;165:51-5.
25. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6: 1399-402.
26. Aikava M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-83.
27. Steiner S, Speidl WS, Pleiner J, et al. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation 2005;111:1841-6.
28. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation: a pilot study. Transplantation 1996;61: 1469-74.
29. Spitzer AL, Harris HW. Statins attenuate sepsis. Surgery 2006;139:283-7.
30. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Artherioscler Thromb Vasc Biol 1995;15:247-51.
31. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588-95.
32. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004;164:2051-7.
33. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999;103:879-87.
34. Serebruany VL, Miller M, Pokov AN, et al. Effect of statins on platelet, PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol 2006;97:1332-6.
35. De Cristofaro R, De Candia E. Thrombin domains: structure, function and interaction with platelet receptors. J Thrombo Thrombolysis 2003;15:151-63.
36. Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003;1:1343-8.
37. Shi J, Wang J, Zheng H, et al. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 2003;14:575-85.
38. Laufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 2000;102:3104-10.
39. Gertz K, Laufs U, Lindauer U, et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 2003;34:551-7.
40. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 2002;91:173-9.
41. Brandes RP, Beer S, Ha T, Busse R. Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003;23:1794-800.
42. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-52.
43. Singhal AB, Topcuoglu MA, Dorer DJ, Ogilvy CS, Carter BS, Koroshetz WJ. SSRI and statin use increases the risk of vasospasm after subarachnoid hemorrhage. Neurology 2005;64:1008-13.
44. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006;32:75-9.
45. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001;33:1352-7.
46. Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006;34:1080-6.
47. Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med 2006;32:160-4.
48. Martin CP, Talbert RL, Burgess DS, Peters JI. Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy 2007;27:20-6.
49. van de Garde EM, Hak E, Souverein PC, Hoes AW, van den Bosch JM, Leufkens HG. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006;61:957-61.
50. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia [online exclusive article]. Respir Res 2005;25:82. Available from http://respiratory-research.com/content/6/1/82.
51. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006;367:413-18.
52. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004;110:880-5.
53. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital and community acquired pneumonia: population based prospective cohort study. BMJ 2006;333:999.
54. McGirt MJ, Blessing R, Alexander MJ, et al. Risk of cerebral vasospasm after subarachnoid hemorrhage reduced by statin therapy: a multivariate analysis of an institutional experience. J Neurosurg 2006;105:671-4.
55. Parra A, Kreiter KT, Williams S, et al. Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: a matched controlled cohort study. Neurosurgery 2005;56:476-84.
56. Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke 2005;36:1627-32.
57. Lynch JR, Wang H, McGirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke 2005;36:2024-6.
58. Singhal AB, Topcuoglu MA, Dorer DJ, Ogilvy CS, Carter BS, Koroshetz WJ. SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage. Neurology 2005;64:1008-13.
59. Shook SJ, Gupta R, Vora NA, Tievsky AL, Katzan I, Krieger DW. Statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke. J Neuroimaging 2006;16:341-6.
60. Aslanyan S, Weir CJ, McInnes GT, Reid JL, Walters MR, Lees KR. Statin administration prior to ischaemic stroke onset and survival: exploratory evidence from matched treatment-control study. Eur J Neurol 2005;12:493-8.
61. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 2005;36:1298-300.
62. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
63. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207-14.
64. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus Conference committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
65. Ho HW, Batjer HH. Aneurysmal subarachnoid hemorrhage: pathophysiology and sequelae. In: Batjer HH, ed. Cerebrovascular disease. Philadelphia: Lippincott-Raven Publishers, 1997:889-99.
66. Biller J, Godersky JC, Adams HP Jr. Management of aneurysmal subarachnoid hemorrhage. Stroke 1988;19:1300-5.
67. Dumont AS, Dumont RJ, Chow MM, et al. Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation. Neurosurgery 2003;53:123-33.
68. Mori T, Nagata K, Town T, Tan J, Matsui T, Asano T. Intracisternal increase of superoxide anion production in a canine subarachnoid hemorrhage model. Stroke 2001;32: 636-42.
69. Horky LL, Pluto RM, Boock RJ, Oldfield EH. Role of ferrous iron chelator 2,2′-dipyridyl in preventing delayed vasospasm in a primate model of subarachnoid hemorrhage. J Neurosurg 1998;88:298-303.
70. McGirt MJ, Lynch JR, Parra A, et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke 2002;33:2950-6.
71. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes, the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999;99:3227-33.
72. Samdani AF, Dawson TM, Dawson VL. Nitric oxide synthase in models of focal ischemia. Stroke 1997;28:1283-8.
73. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999;30:1969-73.
74. Endres M. Statins and stroke. J Cereb Blood Flow Metab 2005;25:1093-110.
75. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase J Biol Chem 1997;272:31725-9.
76. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001;32:980-6.
77. Amerenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59.
78. Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy Circulation 2002;106:1690-5.
79. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
80. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-701.
81. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-92.